Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Jan 18, 2024

BUY
$4.55 - $9.9 $131,040 - $285,120
28,800 Added 1200.0%
31,200 $14,000
Q3 2023

Nov 07, 2023

BUY
$6.72 - $8.6 $16,128 - $20,640
2,400 New
2,400 $5,000

Others Institutions Holding MOR

About MorphoSys AG


  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.